Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

PF-06804103

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Pfizer

Drug class:

Microtubule inhibitor, HER2-targeted antibody-drug conjugate

Related drugs:

‹

ado-trastuzumab emtansine (97)

eribulin mesylate (47)

brentuximab vedotin (29)

disitamab vedotin (27)

mirvetuximab soravtansine-gynx (16)

enfortumab vedotin-ejfv (14)

cabazitaxel (12)

ixabepilone (6)

LR004-VC-MMAE (5)

PF-08046048 (4)

PF-08046047 (4)

belantamab mafodotin-blmf (3)

polatuzumab vedotin-piiq (3)

RGX-019-MMAE (3)

BAY 94-9343 (3)

IMAB027-vcMMAE (2)

PF-06650808 (2)

MF-TTZ-MMAE (1)

PF-06263507 (1)

PF-08046054 (1)

tisotumab vedotin-tftv (1)

estramustine (0)

Nectin-4 ADC (0)

vintafolide (0)

HuMax-AXL-ADC (0)

mebendazole (0)

fam-trastuzumab deruxtecan-nxki (90)

trastuzumab duocarmazine (6)

›

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	PF-06804103 Sensitive: C2 – Inclusion Criteria PF-06804103 Sensitive : C2	PF-06804103 Sensitive: C2 – Inclusion Criteria PF-06804103 Sensitive : C2
HER-2 expression	Gastric Cancer	HER-2 expression	Gastric Cancer	PF-06804103 Sensitive: C2 – Inclusion Criteria PF-06804103 Sensitive : C2	PF-06804103 Sensitive: C2 – Inclusion Criteria PF-06804103 Sensitive : C2
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	PF-06804103 Sensitive: C2 – Inclusion Criteria PF-06804103 Sensitive : C2	PF-06804103 Sensitive: C2 – Inclusion Criteria PF-06804103 Sensitive : C2
HER-2 expression	Non Small Cell Lung Cancer	HER-2 expression	Non Small Cell Lung Cancer	PF-06804103 Sensitive: D – Preclinical PF-06804103 Sensitive : D	PF-06804103 Sensitive: D – Preclinical PF-06804103 Sensitive : D